![](https://investorshub.advfn.com/uicon/105308.png?cb=1488112867)
Friday, November 04, 2011 12:26:15 PM
#1
__________________________________________________________________
Dr Seymour:
We have something better in the works in about 2 weeks time (refer to first email to Dr Seymour from Echo 20, at bottom)
Incidentally, I know there have been complaints about the $5M financing. In light of the world economic situation, it would have been imprudent and irresponsible to turn down this money that has now given us a buffer while we go through the approval process.
Many emerging biotechs fail because of lack of capital. I wanted to guard against that ever happening to us.
Sincerely,
Eugene Seymour, MD MPH
Chief Executive Officer
NanoViricides, Inc
310-486-5677
__________________________________________________________________
Dr. Seymour:
You can post my response from before and from now
There is no evidence that Seaside did a "quick flip" in the past.
Why would anyone assume they would do it now?
Sincerely,
Eugene Seymour, MD MPH
Chief Executive Officer
NanoViricides, Inc
310-486-5677
_______________________________________________________________
First Email from Echo20 to Dr Seymour:
Dr Seymour,
11-3-2011
Here is a statement on webcasts right after conferences at Tekmira.
Maybe NNVC can do similar.
An archived webcast will be available on the Tekmira website approximately two hours after the event. In addition, a replay of the conference call will be available until November 15, 2011 by calling 404-537-3406 or 1-800-585-8367 and referencing conference ID 20403984.
Echo20
Echo20
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM